CNBC’s Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that’s been weighed down by ...

The Department of Justice announced an investigation into Abbott Laboratories' Michigan plant which was at center of a nationwide formula shortage in 2022. Abbott is recalling several of its ready ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

They’re at the center of a legal battle with the makers of specialized formulas for preterm infants — north suburban-based ...

Is the company still worth a look if you're a long-term investor? Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products ...

Also Read: Abbott Laboratories’ Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst. “Our results this quarter demonstrate the strength of our diversified ...

Since my previous article, shares of Abbott Laboratories have returned 10% versus the 7% gains of the S&P 500 index. The healthcare company's sales and adjusted diluted EPS rose in the third quarter.

Abbott Laboratories (NYSE:ABT) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table ...

For Abbott Laboratories, the 200-day moving average sits at $110.38, according to Benzinga Pro, which is below the current price of $117.31. For more on charts and trend lines, see a description here.

Gifting allows recipients to access the article for free. Abbott Laboratories narrowed its full-year profit outlook as strong demand for medical devices, particularly those used by patients with ...

Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast Vandana Singh Wed, Oct 16, 2024, 6:08 AM 2 min read ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...